Skip to main content Accessibility help
×
Home
Hostname: page-component-55597f9d44-54jdg Total loading time: 0.358 Render date: 2022-08-17T01:52:13.569Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true } hasContentIssue true

The Role of Serotonin in Autism-Spectrum Disorders

Published online by Cambridge University Press:  07 November 2014

Abstract

While the etiologies of pervasive developmental disorders (PDDs) appear complicated, multifactorial, and relatively poorly understood research over the last 30 to 40 years has implicated certain neurochemicals in the pathophysiology of these diseases. From these studies, a great deal of evidence has emerged supporting a role for serotonergic dysfunction in individuals with autism and related disorders. Recent clinical trials of drugs influencing serotonergic systems have demonstrated promising effects in children, adolescents, and adults with PDDs.

Type
Feature Article
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994:65-78,417423.Google ScholarPubMed
2.Kaplan, HI, Sadock, BJ, Grebb, JF. Kaplan and Sadock's Synopsis of Psychiatry. 7th ed. Philadelphia, Pa: William & Wilkins; 1994:10521062.Google Scholar
3.Rapin, I. Introduction and overview. In: Bauman, ML, Kemper, TL, eds. The Neurobiology of Autism. Baltimore, Md: The Johns Hopkins University Press; 1994:117.Google ScholarPubMed
4.McDougle, CJ, Kresch, LE, Goodman, WK, et al.A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry. 1995;152:772777.Google ScholarPubMed
5.Lotter, V. Follow-up studies. In: Rutter, M, Schopler, E, eds. Autism: A Reappraisal of Concepts And Treatment. New York, NY: Plenum Press; 1978.Google Scholar
6.Gillberg, C. Outcome in autism and autistic-like conditions. J Am Acad Child Adolesc Psychiatry. 1991;30:375382.CrossRefGoogle ScholarPubMed
7.Gillberg, C, Coleman, M. The Biology of the Autistic Syndromes. 2nd ed. London: MacKeith Press; 1992.Google Scholar
8.Bauman, ML, Kemper, TL. The Neurobiology of Autism. Baltimore, Md: Johns Hopkins University Press; 1994.Google ScholarPubMed
9.McDougle, CJ, Price, LH, Volkmar, FR. Recent advances in the pharmacotherapy of autism and related conditions. In: Volkmar, FR, ed. Psychoses and Pervasive Developmental Disorders. Philadelphia, Pa: W.B. Saunders; 1994:7189.Google Scholar
10.Volkmar, F, Klin, A, Marans, W, McDougle, CJ. Autistic disorder. In: Volkmar, F, ed. Psychoses and Pervasive Developmental Disorders in Childhood and Adolescence. Washington, DC: American Psychiatric Press; 1996:129190.Google Scholar
11.Rubenstein, JLR, Lotspeich, L, Ciaranello, RD. The neurobiology of developmental disorders. In: Lahey, BB, Kazdin, AE, eds. Advances in Clinical Child Psychology. New York, NY: Plenum Publishing Corporation; 1990; 13:152.Google Scholar
12.Gillberg, C, Svennerholm, L, Hamilton-Hellberg, C. Childhood psychosis and monoamine metabolites in spinal fluid. J Autism Dev Disord. 1983;13:383396.CrossRefGoogle ScholarPubMed
13.Campbell, M, Anderson, LT, Meier, M, et al.A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Adolesc Psychiatry. 1978:17:640655.CrossRefGoogle Scholar
14.Cohen, IL, Campbell, M, Posner, D, Small, AM, Triebel, D, Anderson, LT. Behavioral effects of haloperidol in young autistic children. J Am Acad Child Adolesc Psychiatry. 1980;19:665677.CrossRefGoogle ScholarPubMed
15.Anderson, LT, Campbell, M, Grega, DM, Perry, R, Small, AM, Green, WH. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry. 1984; 141:11951202.Google ScholarPubMed
16.Anderson, L, Campbell, M. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord. 1989:19:227239.CrossRefGoogle ScholarPubMed
17.Naruse, H, Nagahata, M, Nakane, Y, Shirahashi, K, Takesada, M, Yamazaki, K. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavior disorders, using cross-over design. Acta Paedopsychiatrica. 1982:48:173184.Google Scholar
18.Schain, RJ, Freedman, DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr. 1961:58:315320.CrossRefGoogle ScholarPubMed
19.Anderson, GM. Monoamines in autism: an update of neurochemical research on a pervasive developmental disorder. Medical Biology. 1987:65:6774.Google ScholarPubMed
20.Narayan, M, Srinath, S, Anderson, GM, Meundi, DB. Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biol Psychiatry. 1993:33:630635.CrossRefGoogle ScholarPubMed
21.Kuperman, S, Beeghly, JH, Burns, TL, Tsai, LY. Serotonin relationships of autistic probands and their first-degree relatives. J Am Acad Child Adolesc Psychiatry. 1985:24:186190.CrossRefGoogle ScholarPubMed
22.Abramson, RK, Wright, HH, Carpenter, R, et al.Elevated blood serotonin in autistic probands and their first-degree relatives. J Autism Dev Disord. 1989:19:397407.CrossRefGoogle ScholarPubMed
23. Cook, E.H.Autism: review of neurochemical investigation. Synapse. 1990:6:292308.CrossRefGoogle ScholarPubMed
24.Leventhal, BL, Cook, EH, Morford, M, Ravitz, A, Freedman, DX. Relationships of whole blood serotonin and norepinephrine within families. J Autism Dev Disord. 1990:20:499511.CrossRefGoogle ScholarPubMed
25.Piven, J, Tsai, GC, Nehme, E, Coyle, JT, Chase, GA, Folstein, SE. Platelet serotonin, a possible marker for familial autism. J Autism Dev Disord. 1991:21:5159.CrossRefGoogle ScholarPubMed
26.Perry, BD, Cook, EH Jr, Leventhal, BL, Wainwright, MS, Freedman, DX. Platelet 5-HT2 serotonin receptor binding sites in autistic children and their first-degree relatives. Biol Psychiatry. 1991:30:121130.CrossRefGoogle ScholarPubMed
27.Hanley, HG, Stahl, SM, Freedman, DX. Hyperserotonemia and amine metabolites in autistic and retarded children. Arch Gen Psychiatry. 1977:34:521531.CrossRefGoogle ScholarPubMed
28.Kuperman, S, Beeghly, J, Burns, T, Tsai, L. Association of serotonin concentration to behavior and IQ in autistic children. J Autism Dev Disord. 1987:17:133140.CrossRefGoogle ScholarPubMed
29.Todd, RD, Ciaranello, RD. Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child. Proc Natl Acad Sci U S A. 1985:82:612616.CrossRefGoogle ScholarPubMed
30.Hoshino, Y, Yamamoto, T, Kaneko, M, et al.Blood serotonin and free tryptophan concentration in autistic children. Neuropsychobiology. 1984; 11:2227.CrossRefGoogle ScholarPubMed
31.McBride, PA, Anderson, GM, Hertzig, ME, et al.Serotonergic responsivity in male young adults with autistic disorder. Results of a pilot study. Arch Gen Psychiatry. 1989;46:213221.CrossRefGoogle Scholar
32.Rose, WC, Haines, WJ, Warner, DT. The amino acid requirements of man. J Biol Chem. 1954:206:421430.Google Scholar
33.Gal, EM, Dreses, PA. Studies on the metabolism of 5-hydrox-ytryptamine (serotonin), II: effect of tryptophan deficiency in rats. Proc Soc Exp Biol Med. 1962:110:368371.CrossRefGoogle Scholar
34.Fernstrom, JD. Effects of the diet on brain neurotransmitters. Metabolism. 1977:26:207223.CrossRefGoogle ScholarPubMed
35.Curzon, G. Influence of plasma tryptophan on brain 5HT synthesis and serotonergic activity. In: Haber, G, Gabay, S, eds. Serotonin: Current Aspects of Neurochemistry and Function. New York, NY: Plenum Press; 1981:207219.CrossRefGoogle Scholar
36.Young, SN, Ervin, FR, Phil, RO, Finn, P. Biochemical aspects of tryptophan depletion in primates. Psychopharmacology (Berl). 1989:95:508511.CrossRefGoogle Scholar
37.Moja, EA, Cipollo, P, Castoldi, D, Tofanetti, O. Dose-response decrease in plasma tryptophan and in brain tryptophan and serotonin after tryptophan-free amino acid mixtures in rats. Life Sci. 1989:44:971976.CrossRefGoogle ScholarPubMed
38.Moir, ATB, Eccleston, D. The effects of precursor loading in the cerebral metabolism of 5-hydroxyindoles. J Neurochem. 1968:15:10931108.CrossRefGoogle ScholarPubMed
39.Fernstrom, JD, Hirsch, MJ. Rapid repletion of brain serotonin in malnourished corn-fed rats following L-tryptophan injection. Life Sci. 1975:17:455464.CrossRefGoogle ScholarPubMed
40.Delgado, PL, Charney, DS, Price, LH, Aghajanian, GK, Landis, H, Heninger, GR. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry. 1990:47:411418.CrossRefGoogle ScholarPubMed
41.Barr, LC, Goodman, WK, McDougle, CJ, et al.Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994:51:309317.CrossRefGoogle ScholarPubMed
42.Delgado, PL, Price, LH, Miller, HL, et al.Serotonin and the neurobiology of depression: effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry. 1994:51:865874.CrossRefGoogle ScholarPubMed
43.Barr, LC, Goodman, WK, Delgado, PL, McDougle, CJ, Price, LH. Effects of tryptophan depletion in drug-free obsessive compulsive disorder patients. Biol Psychiatry. In press.Google Scholar
44.Goddard, AW, Sholomskas, DE, Augeri, FM, et al.Effects of tryptophan depletion in panic disorder. Biol Psychiatry. 1994:36:775777.CrossRefGoogle ScholarPubMed
45.Young, SN, Smith, SE, Pihl, RD, Ervin, FR. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology (Berl). 1985:87:173177.CrossRefGoogle Scholar
46.Smith, SE, Pihl, RO, Young, SWErvin, FR. A test of possible cognitive and environmental influences on the mood lowering effect of tryptophan depletion in normal males. Psychopharmacology. 1987:91:451457.CrossRefGoogle Scholar
47.McDougle, CJ, Naylor, ST, Goodman, WK, Volkmar, FR, Cohen, DJ, Price, LH. Acute tryptophan depletion in autistic disorder: a controlled case study. Biol Psychiatry. 1993:33:547550.CrossRefGoogle Scholar
48.McDougle, CJ, Naylor, ST, Cohen, CJ, Aghajanian, GK, Heninger, GR, Price, LH. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry. 1996:53:9931000.CrossRefGoogle ScholarPubMed
49.Schuster, CR, Lewis, M, Seiden, LS. Fenfluramine: neurotoxicity. Psychopharmacol Bull. 1986:22:148151.Google Scholar
50.Geller, E, Ritvo, ER, Freeman, BJ, Yuwiler, A. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med. 1982:307:165169.CrossRefGoogle ScholarPubMed
51.Ritvo, ER, Freeman, BJ, Geller, E, Yuwiler, A. Effects of fenfluramine on 14 outpatients with the syndrome of autism. J Am Acad Child Adolesc Psychiatry. 1983:22:549558.CrossRefGoogle ScholarPubMed
52.Ritvo, ER, Freeman, BJ, Yuwiler, A, et al.Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers. Psychopharmacol Bull. 1986:22:133140.Google ScholarPubMed
53.Stubbs, EG, Budden, SS, Jackson, RH, Terdal, LG, Ritvo, ER. Effects of fenfluramine on eight outpatients with the syndrome of autism. Dev Med Child Neurol. 1986:28:229235.CrossRefGoogle ScholarPubMed
54.Stern, LM, Walker, MK, Sawyer, MG, Oades, RD, Badcock, NR, Spence, JG. A controlled crossover trial of fenfluramine in autism. J Child Psychol Psychiatry. 1990:31:569585.CrossRefGoogle ScholarPubMed
55.Campbell, M, Perry, R, Small, AM, Green, WH. Overview of drug treatment in autism. In: Schopler, E, Mesibov, GB, eds. Neurobiological Issues in Autism. New York, NY: Plenum Press; 1987.Google Scholar
56.Ekman, G, Miranda-Linné, F, Gillberg, C, Garle, M, Wetterberg, L. Fenfluramine treatment of twenty children with autism. J Autism Dev Disord. 1989;19:511532.CrossRefGoogle ScholarPubMed
57.Sherman, J, Factor, DC, Swinson, R, Darjes, RW. The effects of fenfluramine (hydrochloride) on the behaviors of fifteen autistic children. J Autism Dev Disord. 1989:19:533543.CrossRefGoogle ScholarPubMed
58.Duker, PC, Welles, K, Seys, D, Rensen, H, Vis, A. Brief report: effects of fenfluramine on communicative, stereotypic, and inappropriate behaviors of autistic-type mentally handicapped individuals. J Autism Dev Disord. 1991:21:355363.CrossRefGoogle ScholarPubMed
59.Campbell, M, Fish, B, Shapiro, T, Floyd, AK Jr., Imipramine in preschool autistic and schizophrenic children. Journal of Autism and Childhood Schizophrenia. 1971; 1:267282.CrossRefGoogle ScholarPubMed
60.Fish, B, Campbell, M, Shapiro, T, Floyd, A Jr., Schizophrenic children treated with methysergide (Sansert). Dis Nerv Syst. 1969; 30:534540.Google Scholar
61.Blier, P, de Montigny, C, Chaput, Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry. 1990:51 (suppl):1420.Google Scholar
62.Realmuto, GM, August, GJ, Garfinkel, BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol. 1989:9:122125.CrossRefGoogle ScholarPubMed
63.Ratey, JJ, Sovner, R, Mikkelsen, E, Chmielinski, HE. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry. 1989:50:382384.Google ScholarPubMed
64.Gedye, A. Buspirone alone or with serotonergic diet reduced aggression in a developmentally disabled adult. Biol Psychiatry. 1991:30:8891.CrossRefGoogle ScholarPubMed
65.Ricketts, RW, Goza, AB, Ellis, CR, et al.Clinical effects of buspirone on intractable self-injury in adults with mental retardation. J Am Acad Child Adolesc Psychiatry. 1994:33:270276.CrossRefGoogle Scholar
66.Gedye, A. Serotonergic treatment for aggression in a Down's syndrome adult showing signs of Alzheimer's disease. Journal of Mental Deficiency Research. 1991:35:247258.Google Scholar
67.O'Neill, M, Page, N, Adkins, W. Tryptophan-trazodone treatment of aggressive behavior. Lancet. 1986:2:859860.CrossRefGoogle Scholar
68.McDougle, CJ, Price, LH, Volkmar, FR, et al.Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry. 1992:31:746750.CrossRefGoogle Scholar
69.Garber, HJ, McGonigle, JJ, Slomka, GT, Monteverde, E. Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities. J Am Acad Child Adolesc Psychiatry. 1992:31:11571160.CrossRefGoogle ScholarPubMed
70.Gordon, CT, Rapoport, JL, Hamburger, SD, State, RC, Mannheim, GB. Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am J Psychiatry. 1992:149:363366.Google ScholarPubMed
71.Gordon, CT, State, RC, Nelson, JE, Hamburger, SD, Rapoport, JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993:50:441447.CrossRefGoogle ScholarPubMed
72.Brodkin, ES, McDougle, CJ, Naylor, ST, Cohen, DJ, Price, LH. Clomipramine in adults with pervasive developmental disorders: A prospective, open-label investigation. Journal of Child and Adolescent Psychopharmocology. In press.Google Scholar
73.Brasic, JR, Barnett, JY, Kaplan, D, et al.Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology. 1994:44:13091312.CrossRefGoogle ScholarPubMed
74.Sanchez, LE, Campbell, M, Small, AM, Cueva, JE, Armenteros, JL, Adams, PB. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry. 1996:35:537544.CrossRefGoogle ScholarPubMed
75.Buck, OD. Sertraline for reduction of violent behavior. Am J Psychiatry. 1995:152:953.Google ScholarPubMed
76.Hellings, JA, Kelley, LA, Gabrielli, WF, Kilgore, E, Shah, P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry. 1996:53:333336.Google Scholar
77.Cook, EH Jr, Rowlett, R, Jaselskis, C, Leventhal, BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry. 1992:31:739745.CrossRefGoogle ScholarPubMed
78.Mehlinger, R, Scheftner, WA, Poznanski, E. Fluoxetine and autism. J Am Acad Child Adolesc Psychiatry. 1990:29:985. Letter.CrossRefGoogle ScholarPubMed
79.Hamdan-Allen, G. Brief report: trichotillomania in an autistic male. J Autism Dev Disord. 1991:21:7982.CrossRefGoogle Scholar
80.Todd, RD. Fluoxetine in autism. Am J Psychiatry. 1991:148:1089. Letter.Google Scholar
81.Ghaziuddin, M, Tsai, L, Ghaziuddin, N. Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry. 1991:30:508509. Letter.CrossRefGoogle ScholarPubMed
82.Ghaziuddin, M, Tsai, L. Depression in autistic disorder. Br J Psychiatry. 1991:159:721723.CrossRefGoogle ScholarPubMed
83.Koshes, RJ. Use of fluoxetine for obsessive-compulsive behavior in adults with autism. Am J Psychiatry. 1997:154:578.Google ScholarPubMed
84.Snead, RW, Boon, F, Presberg, J. Paroxetine for self-injurious behavior. J Am Acad Child Adolesc Psychiatry. 1994:33:909910. Letter.CrossRefGoogle ScholarPubMed
85.McDougle, CJ, Price, LH, Goodman, WK. Fluvoxamine treatment of coincident autistic disorder and obsessive compulsive disorder: a case report. J Autism Dev Disord. 1990:20:537543.CrossRefGoogle ScholarPubMed
86.McDougle, CJ, Naylor, ST, Cohen, DJ, Volkmar, FR, Heninger, GR, Price, LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996:53:10011008.CrossRefGoogle ScholarPubMed
87.Goodman, WK, Price, LH, Rasmussen, SA, et al.The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): part I. Development, use, and reliability. Arch Gen Psychiatry. 1989:46:10061011.CrossRefGoogle Scholar
88.Goodman, WK, Price, LH, Rasmussen, SA, et al.The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): part II. Validity. Arch Gen Psychiatry. 1989:46:10121016.CrossRefGoogle Scholar
89.Meltzer, HY. Atypical antipsychotic drugs. In: Bloom, FE, Kupfer, DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:12771286.Google Scholar
90.Potenza, MN, McDougle, CJ. Potential of “atypical” antipsychotics in the treatment of non-psychotic disorders. CNS Drugs. In press.Google Scholar
91.Zuddas, A, Ledda, MG, Fratta, A, Muglia, P, Cianchetti, C. Clinical effects of clozapine on autistic disorder. Am J Psychiatry. 1996:153:738. Letter.Google ScholarPubMed
92.Borison, RL, Pathiraja, AP, Diamond, BL, Meibach, RC. Risperidone clinical safety and efficacy in schizophrenia. Psychopharmacol Bull. 1992:28:213218.Google Scholar
93.Owens, DGC. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry. 1994:55:2935.Google ScholarPubMed
94.Purdon, SE, Lit, WLabelle, A, Jones, BD. Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry. 1994:39:400405.CrossRefGoogle ScholarPubMed
95.McDougle, CJ, Brodkin, ES, Yeung, PP, Naylor, ST, Cohen, DJ, Price, LH. Risperidone in adults with autism or pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology. 1995:5:273282.CrossRefGoogle Scholar
96.Simeon, JG, Carrey, NJ, Wiggins, DM, Milin, RP, Hosendocus, SN. Risperidone effects in treatment-resistant adolescents: preliminary case reports. Journal of Child and Adolescent Psychopharmacology. 1995:5:6979.CrossRefGoogle Scholar
97.Fisman, S, Steele, M, Short, J, Byrne, T, Lavallee, C. Case study: anorexia nervosa and autistic disorder in an adolescent girl. J Am Acad Child Adolesc Psychiatry. 1996:35:937940.CrossRefGoogle Scholar
98.Demb, HB. Risperidone in young children with pervasive developmental disorders and other developmental disabilities. Journal of Child and Adolescent Psychopharmacology 1996:6:7980. Letter.CrossRefGoogle Scholar
99.Fisman, S, Steele, M. Use of risperidone in pervasive developmental disorders: A case series. Journal of Child and Adolescent Psychopharmacology. 1996:6:177190.CrossRefGoogle ScholarPubMed
100.Hardan, A, Johnson, K, Johnson, C, Hrecznyj, B. Case study: risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry. 1996:35:15511556.CrossRefGoogle ScholarPubMed
101.Lott, RS, Kerrick, JM, Cohen, SA. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. Psychopharmacol Bull. 1994:32:721729.Google ScholarPubMed
102.McDougle, CJ, Holmes, JP, Bronson, MR, et al.Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry. 1997(36):685693.CrossRefGoogle ScholarPubMed
103.Bymaster, FP, Calligaro, DO, Falcone, JF, et al.Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996; 14:8796.CrossRefGoogle ScholarPubMed
104.Rubin, MLUse of atypical antipsychotics in children with mental retardation, autism, and other developmental disabilities. Psychiatric Annals. 1997:27:219221.CrossRefGoogle Scholar
105.Megens, AAHP, Niemegeers, CJE, Awouters, FHL. Behavioral disinhibition and depression in amphetaminized rats: a comparison of risperidone, ocaperidone and haloperidol. J Pharmacol Exp Ther. 1992:260:160167.Google ScholarPubMed
106.Dixon, AK, Huber, C, Lowe, DA. Clozapine promotes approach-oriented behavior in male mice. J Clin Psychiatry. 1994;55(suppl B):47.Google ScholarPubMed
107.Prinssen, EPM, Ellenbroek, BA, Cools, AR. Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol. 1994:262:167170.CrossRefGoogle ScholarPubMed
108.Corbett, R, Hartman, H, Kerman, LL, et al.Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav. 1993:45:917.CrossRefGoogle ScholarPubMed
109.van der Linden, C, Bruggeman, R, van Woerkom, TCAM. Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: an open pilot dose-titration study with risperidone. Mov Disord. 1994:9:687688. Letter.CrossRefGoogle ScholarPubMed
110.Swedo, SE, Leonard, HL. Trichotillomania: an obsessive compulsive spectrum disorder? Psychiatric Clin North Am. 1992:15:777790.Google Scholar
111.Swedo, SE, Leonard, HL, Rapoport, JL, Lenane, MC, Goldberger, EL, Cheslow, DL. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med. 1989:321:497501.CrossRefGoogle Scholar
112.Stein, DJ, Hollander, E, Cohen, L, Simeon, D, Aronowitz, B. Serotonergic responsivity in trichotillomania: neuroendocrine effects of m-chlorophenylpiperazine. Biol Psychiatry. 1995:37:414416.CrossRefGoogle Scholar
113.Ninan, FT, Rothbaum, BO, Stipetic, M, Lewine, RJ, Risch, SC. CSF 5-HIAA as a predictor of treatment response in trichotillomania. Psychopharmacol Bull. 1992:28:451455.Google ScholarPubMed
114.Rapoport, JL, Swedo, SE, Leonard, HL. Childhood obsessive-compulsive disorder. J Clin Psychiatry. 1992:53:1116.Google ScholarPubMed
115.Lindley, P, Marks, I, Philpott, R, Snowden, J. Treatment of obsessive-compulsive neurosis with history of childhood autism. Br J Psychiatry. 1977:130:592597.CrossRefGoogle ScholarPubMed
116.McDougle, CJ, Goodman, WK, Price, LH. The pharmacotherapy of obsessive compulsive disorder. Pharmacopsychiatry. 1993;26(suppl):2429.CrossRefGoogle ScholarPubMed
117.Foa, EB. Failures in treating obsessive-compulsives. Behav Res Ther. 1979:17:169176.CrossRefGoogle Scholar
118.Insel, TR, Mueller, EA, Alterman, A, Linnoila, M, Murphy, DL. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry. 1985:20:11741188.CrossRefGoogle Scholar
119.Kanner, L. Autistic disturbances of affective contact. Journal of Nervous Child. 1943:2:217250.Google Scholar
120.McDougle, CJ, Fleischmann, RL, Epperson, CN, Wasylink, S, Leckman, JF, Price, LH. Risperidone addition in fluvoxamine-refractory obsessive compulsive disorder: three cases. J Clin Psychiatry. 1995:56:526528.Google Scholar
121.Saxena, S, Wang, D, Bystritsky, A, Baxter, LR Jr., Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry. 1996:57:303306.Google ScholarPubMed
122.Stein, DJ, Bouwer, MB, Hawkridge, S, Emsley, RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry. 1997:58:119122.CrossRefGoogle ScholarPubMed
19
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

The Role of Serotonin in Autism-Spectrum Disorders
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

The Role of Serotonin in Autism-Spectrum Disorders
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

The Role of Serotonin in Autism-Spectrum Disorders
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *